Related Experiment Video

Updated: Jun 6, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Targeting EGFR Activation to Overcome Gemcitabine Resistance in Cholangiocarcinoma

Sonexai Kidoikhammouan1, Worachart Lert-Itthiporn2, Raksawan Deenonpoe3

  • 1Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen, Thailand.

Anticancer Research
|December 3, 2024
PubMed
Abstract

Insights

Chemotherapy resistance in cholangiocarcinoma (CCA) can be overcome by targeting EGFR. This study found that inhibiting EGFR enhances gemcitabine (Gem) effectiveness against Gem-resistant CCA cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Resistance

Background:

  • Chemotherapy resistance is a significant challenge in treating cholangiocarcinoma (CCA), particularly for patients ineligible for surgery.
  • Gemcitabine (Gem) is a key chemotherapeutic agent, but resistance limits its efficacy.
  • Identifying and targeting molecules associated with Gem resistance is crucial for improving CCA treatment outcomes.

Purpose of the Study:

  • To investigate mechanisms of gemcitabine (Gem) resistance in cholangiocarcinoma (CCA).
  • To identify molecular targets that can overcome Gem resistance.
  • To evaluate the potential of targeting these molecules to enhance Gem's anti-tumor effects in CCA.

Main Methods:

  • Established gemcitabine-resistant CCA cell lines (CCA-GemR) through stepwise drug exposure.
  • Assessed cellular characteristics including growth, cross-resistance, cell cycle, and colony formation.
  • Utilized phosphorylation array and western blotting to identify molecular mechanisms, focusing on EGFR.
  • Analyzed potential targeted therapies using PanDrugs and tested erlotinib in combination with Gem.

Main Results:

  • CCA-GemR cells exhibited slower growth and G1 phase cell cycle arrest.
  • Cross-resistance to 5-FU and cisplatin was observed in all CCA-GemR lines.
  • Increased epidermal growth factor receptor (EGFR) phosphorylation was identified in CCA-GemR cells.
  • Erlotinib (EGFR inhibitor) synergistically enhanced Gem's anti-tumor activity, reducing Gem resistance.

Conclusions:

  • Epidermal growth factor receptor (EGFR) is a key molecule involved in Gem resistance in CCA.
  • Targeting EGFR with inhibitors like erlotinib can overcome Gem resistance.
  • EGFR inhibition enhances the anti-tumor efficacy of Gem in CCA, offering a potential therapeutic strategy.
Keywords:
ChemosensitizingEGFRcholangiocarcinomadrug resistancegemcitabine

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K